Menarini Group Announces Collaboration with VisualDx to Aid in Identifying People Who May Have Blastic Plasmacytoid Dendritic Cell Neoplasm
07.08.2025 - 18:05:38 | prnewswire.co.uk
BPDCN is an aggressive hematologic malignancy with a historically poor prognosisVisualDx is a clinical decision support system used by more than 2,300 hospitals, clinics, and medical schools around the world VisualDx's system seeks to enhance identification of people who may have BPDCN, leveraging actual images of BPDCN skin lesions and artificial intelligence/machine learning (AI/ML) technologies incorporated into the VisualDx platformView original content:https://www.prnewswire.co.uk/news-releases/menarini-group-announces-collaboration-with-visualdx-to-aid-in-identifying-people-who-may-have-blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn-302407123.html
Hol dir jetzt den Wissensvorsprung der Aktien-Profis.
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Aktien-Empfehlungen - Dreimal die Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren.
Für. Immer. Kostenlos
Für. Immer. Kostenlos
boerse | 67967931 |

